The Breast Cancer Now research unit at King's College London is entirely focused on studying triple negative breast cancer.
About our research unit
Triple negative breast cancer can be more aggressive and is more likely to affect younger and black women. And currently, there aren’t enough targeted treatments available for it. That’s why our researchers are looking for new and better ways to treat it.
Our research unit is made up of 15 scientists and led by director Professor Andrew Tutt and deputy director Professor Sheeba Irshad. They're all working together to find what drives triple negative breast cancer, where its weaknesses lie and how to develop new treatments.
Key facts
-
15%
Around 15% of all breast cancers are triple negative.
-
12 scientists
There are 12 scientists working across the 3 research groups.
-
£1,920
It costs £1920 per day to run our Research Unit.
Impact of the research unit
Triple negative trial
A clinical trial that changed how advanced triple negative breast cancer is treated.
Improving chemo drugs
Scientists found that blocking a molecule called PIM1 could potentially be used to boost chemo.
New targets
Researchers discovered a ‘cancer addiction gene’ that could be a new target to treat the disease.
AI to predict spread
Scientists developed an AI model that can predict if triple negative breast cancer will spread.
Teams at our research unit
-
Developing new antibody-based treatments for triple negative breast cancer
Professor Sophia Karagiannis
-
Using AI to understand how triple negative breast cancer responds to treatment
Professor Anita Grigoriadis
